Holen Sie sich die Stockscreener-App
1.56
1.27%
-0.02
Handel nachbörslich:
1.58
0.02
+1.28%
Schlusskurs vom Vortag:
$1.58
Offen:
$1.57
24-Stunden-Volumen:
1.44M
Relative Volume:
0.41
Marktkapitalisierung:
$1.08B
Einnahmen:
$863.49M
Nettoeinkommen (Verlust:
$-188.86M
KGV:
-5.7778
EPS:
-0.27
Netto-Cashflow:
$-44.47M
1W Leistung:
-3.70%
1M Leistung:
+7.59%
6M Leistung:
+20.00%
1J Leistung:
+3.65%
1-Tages-Spanne:
$1.56
$1.585
1-Wochen-Bereich:
$1.55
$1.68
52-Wochen-Spanne:
$0.8516
$1.745
Opko Health Inc Stock (OPK) Company Profile
Firmenname
Opko Health Inc
Sektor
Branche
Telefon
305-575-4181
Adresse
4400 BISCAYNE BLVD., MIAMI, FL
Vergleichen Sie OPK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| OPK | 1.56 | 1.08B | 863.49M | -188.86M | -44.47M | -0.27 |
| TMO | 516.10 | 196.16B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 235.05 | 167.17B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 132.06 | 37.94B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 197.60 | 35.86B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 418.55 | 34.27B | 3.84B | 866.24M | 792.60M | 9.80 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-29 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-24 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-11-25 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-03-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-09-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-06-21 | Bestätigt | Standpoint Research | Buy |
| 2016-06-03 | Eingeleitet | Standpoint Research | Buy |
| 2016-03-31 | Bestätigt | Barrington Research | Outperform |
| 2015-10-16 | Eingeleitet | JP Morgan | Overweight |
| 2015-09-11 | Herabstufung | Jefferies | Buy → Hold |
| 2015-03-03 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2014-05-12 | Bestätigt | Oppenheimer | Outperform |
| 2014-03-14 | Eingeleitet | Oppenheimer | Outperform |
| 2013-11-13 | Bestätigt | Ladenburg Thalmann | Buy |
| 2013-05-30 | Bestätigt | Ladenburg Thalmann | Buy |
| 2012-10-22 | Eingeleitet | Barrington Research | Outperform |
| 2011-12-01 | Bestätigt | Ladenburg Thalmann | Buy |
| 2011-07-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Opko Health Inc Aktie (OPK) Neueste Nachrichten
OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
OPKO Health (OPK) Q3 Earnings Surpass Estimates - MSN
Hyperparathyroidism Treatment Market Growth Trends, Regional - openPR
NextPlat to Showcase OPKO Healthcare Products at Major Chinese Health Expo | NXPLW Stock News - StockTitan
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts - MSN
OPKO Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Opko health CEO Phillip Frost buys $161,980 in stock - Investing.com
Rubric Capital Management LP's Strategic Acquisition in OPKO Hea - GuruFocus.com
Barrington Research Estimates OPKO Health FY2028 Earnings - MarketBeat
Insider Buying: OPKO Health Chairman & CEO Bought US$422k Of Shares - Simply Wall St
Phillip Frost Buys Handful Of Shares In OPKO Health - Yahoo Finance
OPKO Health: Q3 Earnings Snapshot - AOL
OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 280,183 Shares - MarketBeat
OPKO Health's (OPK) Outperform Rating Reiterated at Barrington Research - MarketBeat
OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Simply Wall St
OPKO Health, Inc. (NASDAQ:OPK) Q3 2024 Earnings Call Transcript - Insider Monkey
OPKO Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
Opko health CEO Phillip Frost purchases $421,535 in stock By Investing.com - Investing.com Nigeria
Opko health CEO Phillip Frost purchases $421,535 in stock - Investing.com India
Earnings call: OPKO Health Q3 2024 results show promise amid challenges - Investing.com
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates - StockTitan
OPKO Health Shows Strategic Progress in Q3 2024 - TipRanks
Opko Health (OPK) Q3 2024 Earnings Call Transcript - AOL
Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings - Yahoo Finance
Opko Health earnings beat by $0.12, revenue fell short of estimates - Investing.com Canada
OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results - The Manila Times
Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch® - The Manila Times
Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch® - Yahoo Finance
Health Check-up Market is Expected to Soar in the Upcoming Years - openPR
OPKO Health, Inc. (NASDAQ:OPK) Shares Bought by Assenagon Asset Management S.A. - MarketBeat
OPKO Health (OPK) Set to Announce Earnings on Thursday - MarketBeat
Head to Head Review: OPKO Health (NASDAQ:OPK) vs. OptiNose (NASDAQ:OPTN) - Defense World
OPKO Health, Inc.'s (NASDAQ:OPK) CEO Phillip Frost is the most upbeat insider, and their holdings increased by 9.6% last week - Simply Wall St
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN
OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times
Opko Health Inc (OPK-Q) QuotePress Release - The Globe and Mail
OPKO Health (NASDAQ:OPK) Trading 4.7% HigherShould You Buy? - MarketBeat
SECONDARY HYPERPARATHYROIDISM MARKET TO WITNESS UPSURGE - openPR
Us Prostate Cancer Instruments And Test Market Report: - openPR
With 50% ownership, OPKO Health, Inc. (NASDAQ:OPK) insiders have a lot riding on the company's future - Yahoo Finance
Hypopituitarism Market Forecasted to Surge in Coming Years, - openPR
GeneDx (NASDAQ:WGS) Reaches New 52-Week HighTime to Buy? - MarketBeat
35,157 Shares in OPKO Health, Inc. (NASDAQ:OPK) Bought by Algert Global LLC - Defense World
Renaissance Technologies LLC Cuts Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies - MSN
Finanzdaten der Opko Health Inc-Aktie (OPK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):